Fund Holdings — Rosalind Advisors, Inc.

Total Portfolio Value:
$266.23M
Total Bought:
$36.42M
Total Sold:
$39.85M
Net Transaction:
-$3.43M
Securities
▲▼
SharesValue
Q1 2026
▲▼
Q2 2026
▲▼
Change
▲▼
Q1 2026
▲▼
Q2 2026
▲▼
Weight (%)
▲▼
Change
▲▼
Delcath Systems, Inc.(DCTH)3,300,3893,300,3890$30.63M$41.55M15.61%+$10.92M
Fennec Pharmaceuticals Inc.(FENC)2,908,2013,188,001+279,800$17.89M$34.27M12.87%+$16.39M
Xeris Biopharma Holdings Inc3,231,7002,908,981-322,719$18.74M$23.04M8.65%+$4.30M
Savara Inc.(SVRA)3,203,7213,178,121-25,600$17.49M$19.58M7.35%+$2.08M
Verastem, Inc.(VSTM)2,138,4753,986,509+1,848,034$11.33M$15.23M5.72%+$3.89M
X4 Pharmaceuticals, Inc.(XFOR)3,214,7663,214,7660$13.28M$15.01M5.64%+$1.74M
EyePoint, Inc.(EYPT)1,036,737988,230-48,507$13.36M$14.13M5.31%+$768.1K
Cybin D/B/A Helus Pharma(HELP)1,531,8141,956,814+425,000$7.35M$12.93M4.86%+$5.58M
Vor Biopharma Inc.(VOR)700,000648,600-51,400$12.49M$11.94M4.49%-$547.3K
Vaxcyte, Inc.(PCVX)290,000200,000-90,000$16.85M$11.63M4.37%-$5.23M
MediWound Ltd.SHS NEW(MDWD)749,054749,0540$12.07M$11.01M4.14%-$1.06M
Celldex Therapeutics, Inc.(CLDX)330,000200,000-130,000$10.47M$7.44M2.80%-$3.03M
BioCryst Pharmaceuticals, Inc.(BCRX)923,057721,504-201,553$8.79M$7.22M2.71%-$1.57M
Profound Medical Corp.(PROF)828,118828,1180$5.37M$5.51M2.07%+$140.8K
Talphera, Inc.(TLPH)3,353,9165,169,501+1,815,585$2.51M$5.32M2.00%+$2.82M
Atea Pharmaceuticals, Inc.(AVIR)1,171,8551,070,550-101,305$6.30M$4.98M1.87%-$1.33M
Myomo, Inc.(MYO)3,847,2723,637,886-209,386$2.60M$3.78M1.42%+$1.18M
Ovid Therapeutics Inc.(OVID)1,107,9941,107,9940$2.46M$2.98M1.12%+$520.8K
NeurAxis, Inc.(NRXS)286,138508,055+221,917$1.69M$2.97M1.12%+$1.28M
ABIVAX Société AnonymeADS(ABVX)020,869+20,869$0$2.78M1.04%+$2.78M
InspireMD, Inc.(NSPR)3,905,7433,905,7430$6.37M$2.73M1.03%-$3.63M
Regentis Biomaterials Ltd.(RGNT)251,510701,685+450,175$768.4K$2.48M0.93%+$1.71M
PolyPid Ltd.(PYPD)597,926389,455-208,471$2.62M$1.98M0.74%-$640.5K
Biofrontera Inc.(BFRI)1,163,9621,275,609+111,647$941.6K$1.21M0.45%+$264.4K
Kura Oncology, Inc.(KURA)100,000100,0000$813.0K$1.10M0.41%+$284.0K
Spruce Biosciences Inc020,000+20,000$0$1.08M0.41%+$1.08M
Aquestive Therapeutics Inc250,000250,0000$1.04M$1.04M0.39%+$2.5K
OnKure Therapeutics, Inc.CL A(OKUR)443,763150,000-293,763$1.84M$684.0K0.26%-$1.15M
PepGen Inc.(PEPG)0350,000+350,000$0$630.0K0.24%+$630.0K
Annexon, Inc.(ANNX)200,0000-200,000$1.11M$0—-$1.11M
Avalo Therapeutics, Inc.(AVTX)75,0000-75,000$1.12M$0—-$1.12M
CG Oncology, Inc.(CGON)100,0000-100,000$6.77M$0—-$6.77M
Definium Therapeutics, Inc.(DFTX)125,0000-125,000$2.36M$0—-$2.36M
Lipocine Inc.(LPCN)221,6160-221,616$1.77M$0—-$1.77M
Viridian Therapeutics, Inc.(VRDN)250,4010-250,401$4.90M$0—-$4.90M
Page 1 of 1
Rosalind Advisors, Inc. — 13F Holdings — Q2 2026 | TickerTrail